JPRN-UMIN000050623
Recruiting
未知
Observational study on changes in renal function after new intravitreal drug administration - Observational study on changes in renal function after new intravitreal drug administration
Others0 sites60 target enrollmentApril 1, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Others
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Pregnant women or women who may be pregnant.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenibRenal cell carcinomaJPRN-UMIN000019393Dokkyo Medical University, Department of Urology30
Recruiting
Not Applicable
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosisJPRN-UMIN000040179Hokkaido University400
Not yet recruiting
Not Applicable
A STUDY ON KIDNEY FUNCTION AND FACTORS POINTING AT ACUTE KIDNEY INJURY AFTER KIDNEY STONE REMOVAL SURGERYHealth Condition 1: N200- Calculus of kidneyCTRI/2022/03/040840KMC MANIPA
Completed
Not Applicable
Prospective evaluation of renal function and proteinuria in chronic kidney disease patientsProteinuriaJPRN-UMIN000007371Aichi welfare agricultural cooperative association Anjo Kosei Hospital60
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-005033-31-FRAddmedica S.A.S